+30.4%
MRNA vs AVAV
+31.0%
-0.6%
-86.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | AVAV | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.6% | +2.9% | -6.4% | -4.0% |
| 7D | -9.0% | +3.2% | -12.2% | -9.5% |
| 30D | +137.2% | -20.3% | +157.5% | +145.4% |
| 3M | +194.8% | -19.4% | +214.2% | +202.8% |
| 6M | +167.2% | -35.3% | +202.5% | +179.9% |
| YTD | +375.9% | -38.5% | +414.3% | +392.9% |
| 1Y | +465.2% | -37.2% | +502.4% | +482.4% |
| 3Y | +30.4% | +31.1% | -0.7% | +27.5% |
| All | +30.4% | +31.0% | -0.6% | +27.5% |
Cumulative growth
Daily Returns
Daily percentage return beside AVAV.
Daily Out/Under-Performance
Portfolio return minus AVAV return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × AVAV return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded AVAV wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling